Cargando…
Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208873/ https://www.ncbi.nlm.nih.gov/pubmed/35747844 http://dx.doi.org/10.1097/HS9.0000000000000719 |
| _version_ | 1784729806961639424 |
|---|---|
| author | Petrillo, Alessandra Ip, Andrew Della Pia, Alexandra Gill, Sarvainder Zenreich, Joshua Gutierrez, Martin McNeill, Ann Feldman, Tatyana Leslie, Lori A. Goy, Andre |
| author_facet | Petrillo, Alessandra Ip, Andrew Della Pia, Alexandra Gill, Sarvainder Zenreich, Joshua Gutierrez, Martin McNeill, Ann Feldman, Tatyana Leslie, Lori A. Goy, Andre |
| author_sort | Petrillo, Alessandra |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9208873 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92088732022-06-22 Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Petrillo, Alessandra Ip, Andrew Della Pia, Alexandra Gill, Sarvainder Zenreich, Joshua Gutierrez, Martin McNeill, Ann Feldman, Tatyana Leslie, Lori A. Goy, Andre Hemasphere Letter Lippincott Williams & Wilkins 2022-05-12 /pmc/articles/PMC9208873/ /pubmed/35747844 http://dx.doi.org/10.1097/HS9.0000000000000719 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License (https://creativecommons.org/licenses/by-nc-sa/4.0/) , which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
| spellingShingle | Letter Petrillo, Alessandra Ip, Andrew Della Pia, Alexandra Gill, Sarvainder Zenreich, Joshua Gutierrez, Martin McNeill, Ann Feldman, Tatyana Leslie, Lori A. Goy, Andre Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| title | Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| title_full | Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| title_fullStr | Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| title_full_unstemmed | Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| title_short | Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| title_sort | phase 1b dose-finding study of venetoclax with ibrutinib and rituximab in patients with relapsed/refractory diffuse large b-cell lymphoma |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208873/ https://www.ncbi.nlm.nih.gov/pubmed/35747844 http://dx.doi.org/10.1097/HS9.0000000000000719 |
| work_keys_str_mv | AT petrilloalessandra phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT ipandrew phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT dellapiaalexandra phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT gillsarvainder phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT zenreichjoshua phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT gutierrezmartin phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT mcneillann phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT feldmantatyana phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT leslieloria phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT goyandre phase1bdosefindingstudyofvenetoclaxwithibrutinibandrituximabinpatientswithrelapsedrefractorydiffuselargebcelllymphoma |